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Abstract 
Fibromodulin (FMOD) is known as one of very important extracellular matrix small leucine-rich proteoglycans. This 
small leucine-rich proteoglycan has critical roles in the extracellular matrix organization and necessary for repairing 
of tissue in many organs. Given that the major task of FMOD is the modulation of collagen fibrillogenesis. However, 
recently observed that FMOD plays very important roles in the modulation of a variety of pivotal biological processes 
including angiogenesis, regulation of TGF-β activity, and differentiation of human fibroblasts into pluripotent cells, 
inflammatory mechanisms, apoptosis and metastatic related phenotypes. Besides these roles, FMOD has been con-
sidered as a new tumor-related antigen in some malignancies such as lymphoma, leukemia, and leiomyoma. Taken 
together, these findings proposed that FMOD could be introduced as diagnostic and therapeutic biomarkers in treat-
ment of various cancers. Herein, for first time, we highlighted the various roles of FMOD in the cancerous conditions. 
Moreover, we summarized the diagnostic and therapeutic applications of FMOD in cancer therapy.
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Introduction
Cancer is caused by uncontrolled division of abnormal 
cells which are able to invade other tissues. It is known 
as a result of an imbalance between cell proliferation 
and cell death rate caused by mutations in the regions of 
DNA which code regulator proteins [1]. None isolated 
cells could survive and all cell types need to reside in 
extracellular matrix (ECM) and interact with ECM com-
ponents. The ECM components play important roles in 
tumor formation, as well. Cancer development and its 
progression have been associated with an increase in the 
ECM deposition. The ECM serves not only as a 3-D scaf-
fold required for tissue organization, but also induces a 
series of chemical and physical signals which are crucial 
for survival, proliferation and differentiation of cancer 
cells as well as vascular development and invasion of 
tumor cells [2]. For instance, the ECM is a reservoir for 
various angiogenic growth factors and proteases. ECM 
transduces these signals via ECs integrins and regulates 
their angiogenic phenotype [3]. Stromal cells have been 
recognized as a major source of ECM proteins. However, 
more recently, some studies introduced the cancer cells 
as active and important components involved in ECM 
remodeling [4].
Proteoglycans are relatively small components of ECM 
belonging to the small-leucine-rich-proteoglycan (SLRP) 
family [5], which are categorized into classes I–V [6]. 
Several proteoglycans, such as decorin (Dcn) and bigly-
can from class I, and fibromodulin (FMOD) and lumi-
can from class II, contribute to the regulation of collagen 
fibrillogenesis [7]. Among these proteoglycans, FMOD 
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has been emerged with attractive features which lead to 
affecting on a wide ranges of critical biological processes 
such as angiogenesis, apoptosis, and migration. Multi-
ple lines evidence indicated that FMOD exerts its effects 
via targeting certain signaling pathways such as TGF-β 
[8]. This proteoglycan could play very important roles 
in the initiation and progression of several malignancies 
[9]. Hence, FMOD could be employed as diagnostic and 
therapeutic biomarkers in treatment of different can-
cers. In the current review, for first time, we highlighted 
the various roles of FMOD in the cancerous conditions. 
Moreover, we summarized the diagnostic and therapeu-
tic applications of FMOD in cancer therapy.
FMOD and cancer
FMOD is a main proteoglycan which contributes to 
remodeling of the ECM through binding to matrix mol-
ecules, thereby plays an essential role in tissue repair, 
tumor progression and cancer [10]. The interaction 
between this proteoglycan and lysyl oxidase (LOX; col-
lagen cross-linking enzyme) regulates the ECM com-
position leading to supply an appropriate environment 
for cellular turnover [11]. Moreover, FMOD involves in 
vasculature development and regeneration [12], tumor 
growth suppression and apoptosis prevention [13]. 
It has also been recognized as a growth factor which 
modulates there programming of somatic cells toward 
the pluripotent state [14].
It is believed that FMOD interaction with transform-
ing growth factor (TGF)-β, a key profibrotic cytokine, 
keeps this growth factor within the ECM to regulate 
the action of local TGF-β (Fig. 1). Due to its prominent 
role in regulation of cell growth, differentiation and 
migration, TGF-β is well-known as a key contributor in 
cancer progression. It is a double-edged sword which 
mediates both tumor suppression and promotion 
through instigating the cellular phenotypical changes 
[15]. Even though this growth factor is known to inhibit 
cell proliferation and induce apoptotic cell death during 
the early stages of tumorigenesis, tumor cells may lose 
their growth-inhibitory response to TGF-β resulting 
in inducing epithelial-to-mesenchymal transition and 
promoting cell migration [3, 15].
Fig. 1 TGF-β signaling in cancer progression and tumor suppression
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In addition to its effects on the tumor cells behav-
ior, TGF-β inhibits cell adhesion to the ECM, promotes 
extracellular matrix degradation, and induces immune 
suppression as well as angiogenesis. Through these 
mechanisms, TGF-β modulates the metastasis process 
[3]. Increased secretion of protease and plasmin from 
tumor cells enhances the activation of TGF-β which 
causes extracellular matrix degradation with a subse-
quent release of stored TGF-β. This increased activation 
of TGF-β profoundly affects the micro-environment of 
tumor tissue [16]. TGF-β recruits and activates some 
intracellular signaling pathways including the expres-
sion of several genes, such as fibronectin and collagen, 
specifically Smad and mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) 
pathways. Additionally, FMOD expression is differen-
tially regulated by TGF-β [17]. FMOD function, as a 
regulator of TGF-β, has been observed in scarless wound 
healing and collagen assembly in skin development [18, 
19]. In addition, FMOD shows potential antagonist 
effects on TGF-β regulation, compared with Dcn, in the 
inhibition of neointimal hyperplasia in saphenous vein 
graft [20]. It is also implicated in the inhibition of nuclear 
factor-κB (NF-κB) signaling (a family of transcription fac-
tors) through suppressing the IκBα protein [21]. Dissoci-
ation of IκB domain due to NF-κB activation allows the 
NF-κB dimers to change gene expression and locate in 
the nucleus [22]. Additionally, NF-κB signaling is essen-
tial for epithelial–mesenchymal transition (EMT) and its 
therapeutic inhibition may mitigate tumor invasion and 
metastasis [21]. Besides different pre-clinical studies on 
FMOD, many clinical studies have highlighted the role 
of FMOD in cancer pathogenesis and its diagnostic roles 
(Fig. 2).
In a study, Mayr et al., indicated that there were a sig-
nificant up regulation of FMOD in chronic lymphocytic 
leukemia (CLL) cells than normal B lymphocytes [23]. 
Authors revealed that T cells number were elevated 2- to 
3.5-fold and the number of T cells recognizing FMOD 
peptides bound to HLA-A2 dimers were elevated 10-fold 
during 4  weeks in  vitro. Taken together, these find-
ings proposed that FMOD might be known as potential 
tumor-associated antigen (TAA) in CLL which is able to 
affect on FMOD-specific T cells expansion [23].
Given that FMOD and other members of the pro-
teoglycan family could be involved in collagen 
Fig. 2 Fibromodulin as a pivotal gene for glioma cell migration
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fibrillogenesis and cell adhesion and they also help to 
suppression of tumor growth, regulation of cytokine 
activity, and prevention of apoptosis [24]. FMOD has 
been known as one of TAA in B-CLL which is able 
to provide a specific anti-tumor response. Hence, 
FMOD is potential candidate for cancer immunother-
apy. In a study, Hassan et  al., assessed FMOD expres-
sion in 30 B-CLL subjects and showed the pathogenic 
roles of FMOD in these patients [24]. Their results 
indicated that there was a significant expression of 
FMOD in B-CLL subjects than control group. FMOD 
was expressed in 46.7% of B-CLL subjects. Moreover, 
authors showed that there were a significant relation-
ship between up regulation of FMOD and some risk 
factors which were studied on B-CLL subjects (i.e., 
lower haemoglobin level, lower platelet count, hepato-
megaly, and lower RBCs count) and borderline showed 
a significant relationships with other risk factors such 
as splenomegaly and lymphadenopathy. These findings 
suggested that FMOD has critical roles in the patho-
physiology of CLL [24].
FMOD induces and suppresses apoptosis
The critical roles of FMOD in the pathogenesis of can-
cer had been ignored for a long time. Now, it is clear 
that the regulation of collagen fibrillogenesis and cell 
adhesion are not the only roles of FMOD and the other 
proteoglycans, but they also contribute to apopto-
sis prevention [30, 40]. It has been shown that FMOD 
modulates and suppresses the functions of TGF-β, both 
in vivo and in vitro. For example, it seems that TGF-β 
binding to its binding sites on FMOD inhibits the apop-
totic activity of TGF-β in the B-cell chronic lympho-
cytic leukemia (B-CLL) [30].
NF-κB signaling is another pathway involved in apop-
tosis because its constitutive activation induces cell 
proliferation and inhibits apoptosis [41]. Under normal 
condition, the NF-κB signaling pathway is inhibited by 
a group of inhibitory molecules termed IκB proteins. 
These proteins, such as IκBα, attach to NF-κB to suppress 
its activation in the cytoplasm [42]. FMOD suppresses 
the NF-κB signaling through delaying the degradation 
of IκBα protein byc-Jun N-terminal kinase activation, 
suppression of calpain and casein kinase 2 activity, and 
apoptosis induction [21]. Available data suggests that the 
constitutive turnover of IκBα is mediated by CK2-calpain 
signaling axis which is inactivated in FMOD-expressing 
fibroblasts in a JNK-dependent manner. FMOD expres-
sion is essential for JNK-dependent caspase-3 and cas-
pase-7 activation in 3T3-L1 fibroblasts, suggesting that 
FMOD-mediated activation of JNK promotes apoptosis 
in fibroblasts [41].
FMOD as a promoter for angiogenesis
FMOD is an effective angiogenic factor with important 
roles in cell fate determination. FMOD plays a key role 
in angiogenesis in lung cancer, wound healing, optical 
and cutaneous diseases related to angiogenesis [8, 16, 
43]. It increases the expression of angiogenic growth fac-
tors angiopoietin 2 (ANG2) and VEGF, and inhibits the 
expression of vascular stabilizing factor ANG1. These 
effects indicate that FMOD may regulate further signal-
ing cascades related to growth factors than just TGF-β 
pathway [44].
These angiogenic regulatory effects strongly suggest 
that autocrine-secreted FMOD by cancer cells has a 
stimulating role in tumor angiogenesis of small-cell lung 
cancer. It facilitates the angiogenic phenotype transfor-
mation of endothelial cells as a pro-angiogenic step [8]. 
The role of FOMD in angiogenesis suggests its potential 
abilities in cancer therapy, wound healing, and other con-
ditions associated with abnormal angiogenesis [12, 45].
NF-κB modulates the transcription of several target 
genes implicated in invasion angiogenesis, apoptosis, 
and migration [46, 47]. It has been established to pos-
sess important roles in the progression of breast cancer, 
cell proliferation control and oncogenesis [48]. Glial Cell 
Line-Derived Neurotrophic Factor (GDNF) is a member 
of the TGF-β family. GDNF induces the expression of 
VEGF-C in neu-roblastoma cells and promotes angio-
genesis in renal cells, normal skin cells, and hepatocel-
lular carcinoma cells [49–52]. Chen et al. [53] conducted 
an in vitro study to assess the molecular mechanisms of 
FMOD expression induced by GDNF. To reveal the role 
of GDNF in FMOD expression, they silenced the expres-
sion of GDNF in U251 GBM cells. It was showed that 
GDNF expression silencing suppressed the protein and 
mRNA expression of FMOD. They also demonstrated 
that the secretion of VEGF, as an important pro-angio-
genic factor, transfected with si-FMOD was significantly 
decreased in U251 cells. Furthermore, they indicate that 
GDNF contributes to FMOD promoter demethylation. 
Totally, GDNF promotes FMOD expression in GBM 
cells.
Therefore, the main regulatory roles of FMOD in angi-
ogenesis and apoptosis are associated with TGF-β super-
family as well as NF-κB signaling pathway. Consequently, 
new therapeutic medications could be produced to 
inhibit the development and progression of malignancies 
through regulating these pathways and direct interaction 
with mentioned agents.
FMOD promotes cell migration
FMOD is regulated epigenetically through the meth-
ylation of its promoter. It induces the formation of 
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filamentous actin stress fiber leading to promote the 
migration of glioma cells [31].
The integrins have a main role in linking intracellular 
actin cytoskeleton to the extracellular matrix throughout 
cell migration process [54, 55]. The interaction of integ-
rin with extracellular matrix is transduced into cells by 
activation of integrin-related proteins. Downstream to 
integrins, FAK-Src, as a non-receptor tyrosine kinase, 
has a crucial role in signaling to Rho GTPases [55]. Rho 
GTPases family, including Rho, Rac and Cdc42, contrib-
utes to cytoskeleton remodeling, cell motility and cell 
migration [56]. It has been recently observed that FMOD 
silencing significantly inhibits the TGF-β1-mediated 
migration of glioma cells (Fig. 1) [31].
Mondal and colleagues demonstrated that tumor 
secreted FMOD activates integrin-FAK-Src-Rho GTPase-
dependent signaling to induce the migration of glioma 
cells. They also observed that the remodeling of actin 
cytoskeleton is critical for glioma cell migration induced 
by FMOD [31].
FMOD as a potential novel biomarker
Since effective treatments of early stages of diseases are 
available, new molecular biomarkers are urgently needed 
for an opportune diagnosis and adequate prediction of 
the clinical course of disease [57]. The FMOD gene has 
been considered as a potential biomarker to be more 
evaluated in clinical samples from patients diagnosed 
with benign or malignant prostatic cancers. Validation 
of FMOD transcript in a large population is required to 
ascertain its usefulness as a biomarker of cancer. FMOD 
encodes a proteoglycan which can be detected in differ-
ent body fluids, such as blood, urine or prostatic secre-
tions. Therefore, due to FMOD expression in protein 
level, it is able to differentiate prostate cancer patients 
from the patients with benign disease [34]. Moreover, it 
has been demonstrated that FMOD gene is up-regulated 
in highly malignant glioblastoma compared with rela-
tively benign pilocytic astrocytoma [32]. According to 
this correlation, FMOD could be utilized as a biomarker, 
which indicates the disease severity, at least in the brain 
tumors [44]. It seems that more studies could contribute 
to introduce FMOD as potential biomarker to clinical 
setting in near future.
Targeting FMOD as therapeutic approach in cancer
FMOD has been recognized as a novel tumor-associated 
antigen in lymphoma, leiomyoma, and leukemia [17, 23]. 
FMOD mRNA has been detected different clinical malig-
nancies, such as breast, prostate, and lung carcinomas 
[58–60]. FMOD deficiency decreases interstitial fluid 
pressure and enhances extracellular volume in experi-
mental carcinomas and results in declined collagen fibril 
thickness in experimental carcinoma. It has been previ-
ously indicated that FMOD regulates collagen fibers in 
extracellular environment of tumor [37]. In various can-
cers, the altered small leucine-rich proteoglycans (SLRPs) 
expression, such as decorin, biglycan, and FMOD, has 
been suggested as a diagnostic, prognostic and therapeu-
tic tool (Tables 1, 2) [61]. Recently, it has been shown that 
FMOD, along with other SLRP family members, is not 
only implicated in cell adhesion and collagen fibrillogen-
esis, but also contributes to regulate the tumor growth 
suppression, transcription factors activity, and apoptosis 
prevention [42, 61]. FMOD transcript over expression 
was described in B-cell chronic lymphocytic leukemia 
(CLL-B), and it has been suggested as a target for thera-
peutic approaches in this cancer [23, 24, 30].
In a study, Choudhury et al., assessed the inhibition of 
FMOD and ROR1 in CLL cells [40]. Given that FMOD 
and ROR1 are two genes which are over expressed in 
CLL cells than normal blood B cells. They used siRNAs 
to specifically inhibit expression of FMOD and ROR1 in 
human fibroblast cell lines, healthy B cells and CLL cells 
Their results indicated that utilization of siRNA is able 
to induce a specific decreasing (75–95%) in ROR1 and 
FMOD expression at mRNA levels. Further analysis indi-
cated that 48  h after siRNA treatment the FMOD and 
ROR1 were significantly down regulated at protein lev-
els. Moreover, suppress expression of ROR1 and FMOD 
by using specific siRNAs could be associated with sig-
nificant decreasing of apoptosis of CLL cells but not of 
B cells which was isolated from normal subjects. On the 
other hand, when human fibroblast cell lines were treated 
by ROR1 and FMOD siRNA, there were no observed 
apoptosis. These findings suggested that FMOD and 
ROR1 could be associated with the survival of CLL cells 
and these could be introduced as therapeutic targets in 
the treatment of CLL [40]. In an in vitro study conducted 
by Dawoody Nejad et  al. [21], it was established that 
FMOD over expression is related to TGF-β1 and NF-κB 
down-regulation in metastatic breast cancer cells.
In recently study, Mondal and colleagues indicated 
that FMOD as a GBM over expressed gene because of 
the loss of promoter methylation [31]. They showed that 
the released FMOD enables to induce glioma cell migra-
tion via its ability to enhance formation of filamentous 
actin stress fiber. Utilization of cytochalasin D which 
is an inhibitor for actin polymerization, could signifi-
cantly decrease the FMOD-induced glioma cell migra-
tion. In addition, using siRNA and inhibitor-based small 
molecules revealed that integrin-FAK-Src-Rho-ROCK 
signaling pathway is very important signaling pathway 
which is related to FMOD-induced glioma cell migra-
tion. It has been showed that FMOD without C-terminus 
LRR11 domain (ΔFMOD) is not able to bind collagen 
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Table 1 Role of FMOD in various cancer
CLL chronic lymphocytic leukemia, MCL mantle cell lymphoma, SCLC small cell lung cancer, GBM glioblastoma, ECM extracellular matrix
Cancer type Model Expression Function/signaling pathway Ref
CLL Human Up regulation Expansion of specific CD8 autologous T lymphocytes [23]
Human Up regulation Collagen fibrillogenesis and cell adhesion and contribute to modulation of cytokine activity, 
suppression of tumor growth, and prevention of apoptosis
[24]
Human Up regulation Binds TGF-β and typically negatively modulates its activity overexpression in CLL [25]
Human Up regulation modulation of TGF-β signaling and cell adhesion [26]
Human Up regulation Among the four patients with increase of CTL was observed after the fourth and sixth den-
dritic cell vaccination
[27]
Human Up regulation Tumor progression [28]
Human Up regulation Tumor progression [29]
Human Up regulation Activation of normal B and T lymphocytes, tonsil B cells, CLL B cells, and B-CLL cell lines [30]
GBM Cell line Up regulation Induce migration, promoter methylation and transcript, actin cytoskeleton remodeling/FAK-
Src-Rho-ROCK signaling
[31]
Human Up regulation Generation of neoplastic ECM and induce tumor progression and invasion [32]
Human Up regulation The methylation of FMOD promoter is correlated with good prognosis [33]
Prostate cancer Cell line Up regulation Modulate the activity of transcription factors, suppression of tumor growth and apoptosis 
prevention
[34]
Human Up regulation Regulation of angiogenesis, reprogramming of human fibroblasts into pluripotent cells, 
modulation of TGF-β activity, inflammatory processes and association with metastatic 
phenotypes
[9]
Colon cancer Mouse Down regulation modulation of collagen fibrils in tumor stroma [35]
Cell line Up regulation Increasing of ECM density that inhibit the migration and invasion/collagen types I, III, IV and 
V, biglycan
[36]
Mice Up regulation Prompt the formation of a dense stroma and an elevated interstitial fluid pressure [37]
Leiomyoma Human Up regulation Connective tissue remodeling, specifically fibrillogenesis, cell–cell adhesion and modulation 
of cytokine autocrine/paracrine actions
[17]
Human tumor Up regulation transfection of the cells with Smad3 SiRNA resulted in significant reduction in TGF-β-induced 
FMOD TGF-β, through Smad and MAPK signalling pathways, regulated the expression of 
FMOD
[17]
Myometrium Human Up regulation FMOD regulated by gonadotropin-releasing hormone analogue therapy and TGF-β through 
Smad and MAPK-mediated signaling. Connective tissue remodeling, specifically fibrillogen-
esis, cell–cell adhesion and modulation of cytokine autocrine/paracrine actions
[17]
SCLC Cell line Down regulation Inhibit proliferation, migration, and invasion, angiogenesis/VEGF, TGF-β1, FGF-2, and PDGF-B [38]
MCL Human Up regulation Activation of normal B and T lymphocytes, tonsil B cells [30]
Myxoma Human Up regulation Diagnostic usefulness [39]
Insulinoma Mice Up regulation Inhibition of expression by anti-inflammatory agents showed that FMOD promoted the 
formation of a dense stroma and an elevated interstitial fluid pressure
[37]
Thyroid cancer Mice Up regulation Inhibition of expression by anti-inflammatory agents showed that FMOD promoted the 
formation of a dense stroma and an elevated interstitial fluid pressure
[37]
Table 2 FMOD gene therapy in cancer
Cancer type Model Strategy Function(s) Citation
CLL Cell line Using siRNA against FMOD Induce apoptosis, cells aggregated together and appeared to be granular [40]
Breast cancer Cell line Using recombinant Adenovirus FMOD Suppresses NF-κB DNA binding and TGF-β1 that control of cell proliferation 
and oncogenesis
[21]
Leukemia Cell line Using siRNA against FMOD Diminished the apoptosis of B-CLL cells [62]
Glioblastoma Cell line Using RNAi against FMOD Induce glioma cell migration and invasion by promoting actin cytoskeleton 
remodeling pathway
[31]
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type I and could not also induce integrin and glioma cell 
migration. A 9-mer wild-type peptide originated from 
the FMOD C-terminus could inhibit the activation of 
FMOD-induced integrin and migration. The Chroma-
tin immunoprecipitation-PCR analyses indicated that 
transforming TGF-β1 is able to modulate expression 
of FMOD via epigenetic FMOD promoter remodeling. 
The silencing of FMOD is associated with inhibition of 
TGF-β1-mediated GBM cell migration. Multivariate Cox 
regression analysis, demonstrated that promoter methyl-
ation and transcript levels of FMOD could predict prog-
nosis in GBM. Collectively, using specific siRNA against 
FMOD could show therapeutic effects via inhibition of 
TGF-β1 pathway. Thus, FMOD is a potential target in 
treatment of GBM [31].
Conclusion
Current data suggest the important role of FMOD in the 
pathogenesis of cancer. This proteoglycan interacts with 
cellular and molecular mechanisms, such as NF-kB, to 
develop malignancy. FMOD acts through increasing the 
migration and angiogenesis to progress cancer. It also 
suppresses the apoptosis induction.
Despite several attempts on this horizon, studies on 
FMOD are associated with some limitations. It seems 
that more pre-clinical experiments and clinical studies 
(with large samples) could contribute to more under-
standing of FMOD roles in the cancer pathogenesis. 
Moreover, more assessments could help to introduce 
this molecule as diagnostic or prognostic biomarkers for 
monitoring cancer subjects. This review suggest, evalu-
ation of FMOD in all cancerous conditions may lead to 
introduce it to clinical settings.
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